Article
Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
European urology - 1 Mar 2015
Risbridger Gail P, Taylor Renea A, Clouston David, Sliwinski Ania, Thorne Heather, Hunter Sally, Li Jason, Mitchell Gillian, Murphy Declan, Frydenberg Mark, Pook David, Pedersen John, Toivanen Roxanne, Wang Hong, Papargiris Melissa, Lawrence Mitchell G, Bolton Damien M
Abstract excerpt
BACKGROUND: Intraductal carcinoma of the prostate (IDC-P) is a distinct clinicopathologic entity associated with aggressive prostate cancer (PCa). PCa patients carrying a breast cancer 2, early onset (BRCA2) germline mutation exhibit highly aggressive tumours with poor prognosis. OBJECTIVE: To investigate the presence and implications of IDC-P in men with a strong family history of PCa who either carry a BRCA2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.